Cell>Point Submits Investigational New Drug Application for Phase 1b/2 Trial of 99mTc-EC-G in Assessing Coronary Artery Disease

Published: Jun 22, 2010

CENTENNIAL, Colo.--(BUSINESS WIRE)--Cell>Point announced today that it has submitted to the Food and Drug Administration an Investigational New Drug (IND) application for a Phase 1b/2 trial of its 99mTc-EC-G diagnostic in assessing patients with Coronary Artery Disease (CAD).

Back to news